Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference newsletter

  Breast Cancer

  Free Subscription


2 Acta Cytol
2 Am J Surg
1 Ann Oncol
4 Ann Surg Oncol
2 BMC Cancer
2 Br J Cancer
2 Breast Cancer
2 Breast Cancer (Auckl)
2 Breast Cancer Res
27 Breast Cancer Res Treat
4 Breast J
2 Cancer
1 Cancer Cell
2 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
2 Cancer Res
5 Clin Breast Cancer
2 Clin Cancer Res
3 Clin Exp Metastasis
1 Exp Cell Res
1 Histopathology
2 Int J Radiat Oncol Biol Phys
1 J Biol Chem
2 J Clin Oncol
1 J Natl Cancer Inst
1 Lancet Oncol
1 N Engl J Med
1 Oncogene
1 PLoS Med
1 PLoS One
1 Proc Natl Acad Sci U S A
3 Radiother Oncol
3 Semin Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Cytol

  1. LAYFIELD LJ, Wang G, Yang ZJ, Gomez-Fernandez C, et al
    Interobserver Agreement for the International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology.
    Acta Cytol. 2020;64:413-419.
    PubMed         Abstract available

  2. DIXIT S, Tanveer N, Kumar H, Diwan H, et al
    Smartphone-Assisted Telecytopathology: An Intraobserver Concordance Study.
    Acta Cytol. 2020;64:399-405.
    PubMed         Abstract available

    Am J Surg

  3. FRANCESCHINI G, Masetti R
    Evidence-based nipple-sparing mastectomy in patients with higher body mass index: Recommendations for a successful standardized surgery.
    Am J Surg. 2020;220:393-394.
    PubMed         Abstract available

  4. KOSASIH S, Tayeh S, Mokbel K, Kasem A, et al
    Is oncoplastic breast conserving surgery oncologically safe? A meta-analysis of 18,103 patients.
    Am J Surg. 2020;220:385-392.
    PubMed         Abstract available

    Ann Oncol

  5. CARDOSO F, Kyriakides S, Ohno S, Penault-Llorca F, et al
    Erratum to "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": Annals of Oncology 30; 2019: 1194-1220.
    Ann Oncol. 2020 Sep 7. pii: S0923-7534(20)42223.

    Ann Surg Oncol

  6. ALBERTY-OLLER JJ, Weltz S, Santos A, Pisapati K, et al
    Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?
    Ann Surg Oncol. 2020 Sep 11. pii: 10.1245/s10434-020-09123.
    PubMed         Abstract available

  7. BAUMRUCKER CC, Spring SR, Cohen BL, Millen JC, et al
    The Effect of Hospital Volume on Outcomes of Patients with Occult Breast Cancer.
    Ann Surg Oncol. 2020 Sep 10. pii: 10.1245/s10434-020-09103.
    PubMed         Abstract available

  8. BHUROSY T, Niu Z, Heckman CJ
    Breastfeeding is Possible: A Systematic Review on the Feasibility and Challenges of Breastfeeding Among Breast Cancer Survivors of Reproductive Age.
    Ann Surg Oncol. 2020 Sep 11. pii: 10.1245/s10434-020-09094.
    PubMed         Abstract available

  9. NAYYAR A, Strassle PD, Iles K, Jameison D, et al
    Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women.
    Ann Surg Oncol. 2020 Sep 11. pii: 10.1245/s10434-020-08945.
    PubMed         Abstract available

    BMC Cancer

  10. MURILLO-ORTIZ B, Hernandez-Ramirez A, Rivera-Villanueva T, Suarez-Garcia D, et al
    Monofrequency electrical impedance mammography (EIM) diagnostic system in breast cancer screening.
    BMC Cancer. 2020;20:876.
    PubMed         Abstract available

  11. CAI YC, Yang H, Wang KF, Chen TH, et al
    ANGPTL4 overexpression inhibits tumor cell adhesion and migration and predicts favorable prognosis of triple-negative breast cancer.
    BMC Cancer. 2020;20:878.
    PubMed         Abstract available

    Br J Cancer

  12. HU Y, Xu W, Zeng H, He Z, et al
    OXPHOS-dependent metabolic reprogramming prompts metastatic potential of breast cancer cells under osteogenic differentiation.
    Br J Cancer. 2020 Sep 16. pii: 10.1038/s41416-020-01040.
    PubMed         Abstract available

  13. OLAFSDOTTIR EJ, Borg A, Jensen MB, Gerdes AM, et al
    Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status.
    Br J Cancer. 2020 Sep 17. pii: 10.1038/s41416-020-01056.
    PubMed         Abstract available

    Breast Cancer

  14. ZHAO JM, An Q, Sun CN, Li YB, et al
    Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
    Breast Cancer. 2020 Sep 17. pii: 10.1007/s12282-020-01158.
    PubMed         Abstract available

  15. VUKSANOVIC D, Sanmugarajah J, Lunn D, Sawhney R, et al
    Unmet needs in breast cancer survivors are common, and multidisciplinary care is underutilised: the Survivorship Needs Assessment Project.
    Breast Cancer. 2020 Sep 14. pii: 10.1007/s12282-020-01156.
    PubMed         Abstract available

    Breast Cancer (Auckl)

  16. FLORES-LUEVANO S, Shokar NK, Dwivedi AK, Shokar GS, et al
    Breast Cancer Fear Among Mexican American Women in the United States.
    Breast Cancer (Auckl). 2020;14:1178223420952745.
    PubMed         Abstract available

  17. AKHOURI V, Kumar A, Kumari M
    Antitumour Property of Pterocarpus santalinus Seeds Against DMBA-Induced Breast Cancer in Rats.
    Breast Cancer (Auckl). 2020;14:1178223420951193.
    PubMed         Abstract available

    Breast Cancer Res

  18. JAGER A, de Vries EGE, der Houven van Oordt CWM, Neven P, et al
    A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging.
    Breast Cancer Res. 2020;22:97.
    PubMed         Abstract available

  19. CABEL L, Rosenblum D, Lerebours F, Brain E, et al
    Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Breast Cancer Res. 2020;22:98.
    PubMed         Abstract available

    Breast Cancer Res Treat

  20. MONTAGNA E, Pagan E, Bagnardi V, Colleoni M, et al
    Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study.
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05900.
    PubMed         Abstract available

  21. LEE KT, Jacobs L, Walsh EM, Stearns V, et al
    Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05910.
    PubMed         Abstract available

  22. DE REZENDE LF, Francisco VE, Franco RL
    Telerehabilitation for patients with breast cancer through the COVID-19 pandemic.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05926.

    Breast Cancer Res Treat. 2020;179:1.

  24. DE AZAMBUJA E, Ponde N, Procter M, Rastogi P, et al
    A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.
    Breast Cancer Res Treat. 2020;179:161-171.
    PubMed         Abstract available

  25. HAWSE JR, Carter JM, Aspros KGM, Bruinsma ES, et al
    Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues.
    Breast Cancer Res Treat. 2020;179:241-249.
    PubMed         Abstract available

  26. GOLDFARB SB, Turan V, Bedoschi G, Taylan E, et al
    Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.
    Breast Cancer Res Treat. 2020 Sep 15. pii: 10.1007/s10549-020-05933.
    PubMed         Abstract available

  27. YUSUFOV M, Nathan M, Wiley A, Russell J, et al
    Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05920.
    PubMed         Abstract available

  28. VAN NIJNATTEN TJA, van Tiel LPT, Voogd AC, Groothuis-Oudshoorn CGM, et al
    The effect of breast MRI on disease-free and overall survival in breast cancer patients: a retrospective population-based study.
    Breast Cancer Res Treat. 2020 Sep 15. pii: 10.1007/s10549-020-05906.
    PubMed         Abstract available

  29. WANG B, Huang T, Fang Q, Zhang X, et al
    Bone-protective and anti-tumor effect of baicalin in osteotropic breast cancer via induction of apoptosis.
    Breast Cancer Res Treat. 2020 Sep 16. pii: 10.1007/s10549-020-05904.
    PubMed         Abstract available

  30. LOSK K, Freedman RA, Laws A, Kantor O, et al
    Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
    Breast Cancer Res Treat. 2020 Sep 16. pii: 10.1007/s10549-020-05931.
    PubMed         Abstract available

  31. DENT SF, Botros J, Rushton M, Aseyev O, et al
    Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.
    Breast Cancer Res Treat. 2020 Sep 17. pii: 10.1007/s10549-020-05887.
    PubMed         Abstract available

  32. XUE L, Chen F, Yue F, Camacho L, et al
    Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Sep 17. pii: 10.1007/s10549-020-05927.
    PubMed         Abstract available

  33. SOLLENA P, Nikolaou V, Soupos N, Kotteas E, et al
    Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05914.
    PubMed         Abstract available

  34. YANG Y, Zhao J, Mao Y, Lin G, et al
    UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing beta-catenin.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05899.
    PubMed         Abstract available

  35. LIN Y, Lin L, Fu F, Wang C, et al
    Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05916.
    PubMed         Abstract available

  36. VOGSEN M, Jensen JD, Christensen IY, Gerke O, et al
    FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05929.
    PubMed         Abstract available

  37. FRISELL A, Lagergren J, Halle M, de Boniface J, et al
    Risk factors for implant failure following revision surgery in breast cancer patients with a previous immediate implant-based breast reconstruction.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05911.
    PubMed         Abstract available

  38. MENEVEAU MO, Keim-Malpass J, Camacho TF, Anderson RT, et al
    Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05908.
    PubMed         Abstract available

  39. ABDELHAFEZ AH, Musall BC, Adrada BE, Hess K, et al
    Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
    Breast Cancer Res Treat. 2020 Sep 13. pii: 10.1007/s10549-020-05917.
    PubMed         Abstract available

  40. KOU K, Cameron J, Aitken JF, Youl P, et al
    Factors associated with being diagnosed with high severity of breast cancer: a population-based study in Queensland, Australia.
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05905.
    PubMed         Abstract available

  41. HAN Y, Miao ZF, Lian M, Peterson LL, et al
    Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05902.
    PubMed         Abstract available

  42. TAKAHASHI M, Ohtani S, Nagai SE, Takashima S, et al
    The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
    Breast Cancer Res Treat. 2020 Sep 13. pii: 10.1007/s10549-020-05921.
    PubMed         Abstract available

  43. PALLESCHI M, Scarpi E, Casadei C
    Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
    Breast Cancer Res Treat. 2020 Sep 14. pii: 10.1007/s10549-020-05923.

  44. MAO D, Hachem H, Chang H, Dima D, et al
    Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients.
    Breast Cancer Res Treat. 2020 Sep 12. pii: 10.1007/s10549-020-05892.
    PubMed         Abstract available

  45. CALIP GS, Kidd J, Bernhisel R, Cox HC, et al
    Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.
    Breast Cancer Res Treat. 2020 Sep 11. pii: 10.1007/s10549-020-05922.
    PubMed         Abstract available

  46. XING CY, Doose M, Qin B, Lin Y, et al
    Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors.
    Breast Cancer Res Treat. 2020 Sep 10. pii: 10.1007/s10549-020-05901.
    PubMed         Abstract available

    Breast J

  47. VALENTE S, Al-Hilli Z, Liu Y, Greve N, et al
    Association of patient factors with time to treatment for breast cancer.
    Breast J. 2020 Sep 13. doi: 10.1111/tbj.14046.
    PubMed         Abstract available

  48. GIULIANI J, Bonetti A
    The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence.
    Breast J. 2020 Sep 13. doi: 10.1111/tbj.14024.

  49. MOSTAFAEI S, Vahidi Manesh P, Sadri Nahand J, Nesaei A, et al
    The role of Epstein-Barr virus-expressed genes in breast cancer development.
    Breast J. 2020 Sep 11. doi: 10.1111/tbj.14021.

  50. SITTENFELD SMC, Murray E, Guo B, Tendulkar R, et al
    Treatment of diffuse cutaneous metastases from breast cancer.
    Breast J. 2020 Sep 11. doi: 10.1111/tbj.14049.


  51. PENG SM, Yang KC, Chan WP, Wang YW, et al
    Impact of the COVID-19 pandemic on a population-based breast cancer screening program.
    Cancer. 2020 Sep 11. doi: 10.1002/cncr.33180.

  52. MARMOR S, Longacre CF, Altman AM, Hui JYC, et al
    Genomic expression assay testing among American Indian and Alaska Native women with breast cancer.
    Cancer. 2020 Sep 14. doi: 10.1002/cncr.33150.
    PubMed         Abstract available

    Cancer Cell

  53. PUSZTAI L, Taylor R, Mougalian SS
    Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer.
    Cancer Cell. 2020;38:323-325.
    PubMed         Abstract available

    Cancer Epidemiol Biomarkers Prev

  54. SANTALA EEE, Murto MO, Artama M, Pukkala E, et al
    Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival-A Nationwide Cohort Study from Finland.
    Cancer Epidemiol Biomarkers Prev. 2020 Sep 11. pii: 1055-9965.EPI-20-0711.
    PubMed         Abstract available

  55. KENSLER KH, Liu EZF, Wetstein SC, Onken AM, et al
    Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk.
    Cancer Epidemiol Biomarkers Prev. 2020 Sep 11. pii: 1055-9965.EPI-20-0723.
    PubMed         Abstract available

    Cancer Lett

  56. LI Y, Zhang H, Li Q, Zou P, et al
    CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
    Cancer Lett. 2020 Sep 14. pii: S0304-3835(20)30473.
    PubMed         Abstract available

    Cancer Res

  57. BHAT-NAKSHATRI P, Kumar B, Simpson E, Ludwig KK, et al
    Breast cancer cell detection and characterization from breast milk-derived cells.
    Cancer Res. 2020 Sep 15. pii: 0008-5472.CAN-20-1030.
    PubMed         Abstract available

  58. HUANG M, O'Shaughnessy J, Zhao J, Haiderali A, et al
    Association of Pathological Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-analysis.
    Cancer Res. 2020 Sep 14. pii: 0008-5472.CAN-20-1792.
    PubMed         Abstract available

    Clin Breast Cancer

  59. COBB AN, Janjua HM, Kuo PC
    Big Data Solutions for Controversies in Breast Cancer Treatment.
    Clin Breast Cancer. 2020 Aug 12. pii: S1526-8209(20)30208.
    PubMed         Abstract available

  60. SAVVA C, Sadiq M, Sheikh O, Karim S, et al
    Werner Syndrome Protein Expression in Breast Cancer.
    Clin Breast Cancer. 2020 Jul 25. pii: S1526-8209(20)30179.
    PubMed         Abstract available

  61. JOHN P, Osani MC, Kodali A, Buchsbaum R, et al
    Comparative Effectiveness of Adjuvant Chemotherapy in Early-Stage Breast Cancer: A Network Meta-analysis.
    Clin Breast Cancer. 2020 Jul 14. pii: S1526-8209(20)30171.
    PubMed         Abstract available

  62. ANDRIKOPOULOU A, Zografos E, Liontos M, Koutsoukos K, et al
    Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer.
    Clin Breast Cancer. 2020 Aug 18. pii: S1526-8209(20)30211.
    PubMed         Abstract available

  63. BILANI N, Elson L, Liang H, Elimimian EB, et al
    Effect of Surgery at Primary and Metastatic Sites in Patients with Stage IV Breast Cancer.
    Clin Breast Cancer. 2020 Aug 18. pii: S1526-8209(20)30214.
    PubMed         Abstract available

    Clin Cancer Res

  64. CHAN N, Willis A, Kornhauser N, Ward MM, et al
    Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
    Clin Cancer Res. 2020;26:5051.

  65. CIRUELOS EM, Villagrasa P, Pascual T, Oliveira M, et al
    Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial.
    Clin Cancer Res. 2020 Sep 16. pii: 1078-0432.CCR-20-0844.
    PubMed         Abstract available

    Clin Exp Metastasis

  66. BROWN DA, Lu VM, Himes BT, Burns TC, et al
    Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis.
    Clin Exp Metastasis. 2020;37:341-352.
    PubMed         Abstract available

  67. CHENG JN, Frye JB, Whitman SA, Funk JL, et al
    Skeletal impact of 17beta-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation.
    Clin Exp Metastasis. 2020;37:269-281.
    PubMed         Abstract available

  68. YOUNSI A, Riemann L, Scherer M, Unterberg A, et al
    Impact of decompressive laminectomy on the functional outcome of patients with metastatic spinal cord compression and neurological impairment.
    Clin Exp Metastasis. 2020;37:377-390.
    PubMed         Abstract available

    Exp Cell Res

  69. UMAR SM, Kashyap A, Kahol S, Mathur S, et al
    Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer.
    Exp Cell Res. 2020 Sep 10:112282. doi: 10.1016/j.yexcr.2020.112282.
    PubMed         Abstract available


  70. NOSKE A, Ammann JU, Wagner DC, Denkert C, et al
    A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays for scoring in triple-negative breast cancer.
    Histopathology. 2020 Sep 16. doi: 10.1111/his.14254.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  71. LETTAU K, Zips D, Toulany M
    Simultaneous targeting of RSK and AKT efficiently inhibits YB-1-mediated repair of ionizing radiation-induced DNA double strand breaks in breast cancer cells.
    Int J Radiat Oncol Biol Phys. 2020 Sep 12. pii: S0360-3016(20)34270.
    PubMed         Abstract available

  72. WOODWARD SG, Varshney K, Anne PR, George BJ, et al
    Trends in Utilization of Hypofractionated Whole Breast Radiation in Breast Cancer: An Analysis of the National Cancer Database.
    Int J Radiat Oncol Biol Phys. 2020 Sep 12. pii: S0360-3016(20)34269.
    PubMed         Abstract available

    J Biol Chem

  73. JOSHI R, Qin L, Cao X, Zhong S, et al
    DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.
    J Biol Chem. 2020;295:645-656.
    PubMed         Abstract available

    J Clin Oncol

  74. SAWAKI M, Taira N, Uemura Y, Saito T, et al
    Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
    J Clin Oncol. 2020 Sep 16:JCO2000184. doi: 10.1200/JCO.20.00184.
    PubMed         Abstract available

  75. DE AZAMBUJA E, Ponde N, Gelber RD
    Are We RESPECTing Older Patients With Breast Cancer?
    J Clin Oncol. 2020 Sep 16:JCO2002329. doi: 10.1200/JCO.20.02329.

    J Natl Cancer Inst

  76. O'LEARY B, Cutts RJ, Huang X, Hrebien S, et al
    Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
    J Natl Cancer Inst. 2020 Jun 17. pii: 5858980. doi: 10.1093.
    PubMed         Abstract available


    RNA Aptamers Deliver Chemotherapy Directly to Tumors.
    JAMA. 2020;324:829.

    Lancet Oncol

  78. TURNER NC, Kingston B, Kilburn LS, Kernaghan S, et al
    Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
    Lancet Oncol. 2020 Sep 10. pii: S1470-2045(20)30444.
    PubMed         Abstract available

    N Engl J Med

    When E-Cadherin Becomes Unstuck in Cancer.
    N Engl J Med. 2020;383:871-873.


  80. DOHENY D, Sirkisoon S, Carpenter RL, Aguayo NR, et al
    Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
    Oncogene. 2020 Sep 14. pii: 10.1038/s41388-020-01454.
    PubMed         Abstract available

    PLoS Med

  81. JOHNSON KE, Siewert KM, Klarin D, Damrauer SM, et al
    The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study.
    PLoS Med. 2020;17:e1003302.
    PubMed         Abstract available

    PLoS One

  82. TANIGUCHI K, Takada S, Omori M, Igawa T, et al
    Triple-negative pleomorphic lobular carcinoma and expression of androgen receptor: Personal case series and review of the literature.
    PLoS One. 2020;15:e0235790.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  83. MCLAUGHLIN LJ, Stojanovic L, Kogan AA, Rutherford JL, et al
    Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.
    Proc Natl Acad Sci U S A. 2020;117:17785-17795.
    PubMed         Abstract available

    Radiother Oncol

  84. HUANG H, Roberson J, Hou W, Mani K, et al
    NTCP model for hypothyroidism after supraclavicular-directed radiation therapy for breast cancer.
    Radiother Oncol. 2020 Sep 11. pii: S0167-8140(20)30772.
    PubMed         Abstract available

  85. JOSEPH K, Zebak S, Alba V, Mah K, et al
    Adjuvant breast radiotherapy, endocrine therapy after breast conserving surgery in older women with low-risk breast cancer: Results from a population-based study.
    Radiother Oncol. 2020 Sep 14. pii: S0167-8140(20)30789.
    PubMed         Abstract available

  86. FINNEGAN R, Lorenzen EL, Dowling J, Jensen I, et al
    Analysis of Cardiac Substructure Dose in a Large, Multi-Centre Danish Breast Cancer Cohort (the DBCG HYPO trial): Trends and Predictive Modelling.
    Radiother Oncol. 2020 Sep 8. pii: S0167-8140(20)30773.
    PubMed         Abstract available

    Semin Oncol

  87. T'KINT DE ROODENBEKE MD, Ponde N, Buisseret L, Piccart M, et al
    Management of early breast cancer in patients bearing germline BRCA mutations.
    Semin Oncol. 2020 Aug 18. pii: S0093-7754(20)30083.
    PubMed         Abstract available

  88. CHIEC L, Shah AN
    Risk-based Approaches for Optimizing Treatment in HER2-Positive Early Stage Breast Cancer.
    Semin Oncol. 2020 Aug 20. pii: S0093-7754(20)30084.
    PubMed         Abstract available

  89. HENSING W, Santa-Maria CA, Peterson LL, Sheng JY, et al
    Landmark trials in the medical oncology management of early stage breast cancer.
    Semin Oncol. 2020 Aug 30. pii: S0093-7754(20)30088.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.